‘We Are Well Positioned To Succeed’: Organon On US Adalimumab Entry
Exclusive Interview With Organon’s US Biosimilars Commercial Lead, Jon Martin
Executive Summary
With Organon’s Humira biosimilar Hadlima reaching the US market earlier this month, the company’s biosimilars commercial lead in the market, Jon Martin, spoke to Generics Bulletin about the seminal event, as well as the company’s commercialization-only business model.
You may also be interested in...
Fresh Wave Of Adalimumab Biosimilars Hits US
As launch dates arrive under settlement agreements with Humira originator AbbVie, multiple firms have introduced adalimumab biosimilars in the US, confirming launch and pricing details – with one biosimilar following in the footsteps of Coherus by announcing an 85% discount to the originator.
Organon: ‘Those $4bn-$5bn Biologics – That’s A Nice Place To Play In Biosimilars’
Joe Azzinaro, Organon’s global commercial leader for biosimilars, sat down to talk with Generics Bulletin about its commercialization expertise and investments for the future.
Organon Strikes $100m+ Global Deal For Henlius’ Denosumab And Pertuzumab
Organon has agreed to pay an upfront price of $73m plus potentially a further $30m in milestone payments this year alone for the rights to Shanghai Henlius Biotech’s HLX14 denosumab and HLX11 pertuzumab biosimilar candidates outside China. The deal also offers Organon an option to negotiate with Henlius for rights to its ipilimumab biosimilar.